New River Pharma-NRPH October 25 straddle is Expensive into PDUFA
Oct 4
NRPH, is a specialty pharmaceutical company developing treatments for
attention-deficit/hyperactivity disorders (ADHD). The FDA PDUFA decision for the
approval of NRP104 is expected before 10/6/06. NRPH recently traded at $25.24.
NRPH October 25 straddle is priced at $10.10 according to Track Data. October
front month Equity Options expire; Friday, 10/20/06. Expensive straddles
indicates aggressive risk.